| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Butyrylcarnitine is an endogenous metabolite involved in fatty acid and amino acid metabolism. It does not have a specific pharmacological target. It is a biomarker of metabolic dysfunction. It serves as a reference standard in metabolomics and clinical chemistry. It is indicative of anomalous lipid and energy metabolism.
|
|---|---|
| ln Vitro |
In vitro, butyrylcarnitine is used as a reference standard and biomarker in metabolomics studies. It is detected in plasma samples and its levels are measured by mass spectrometry. It does not have direct pharmacological activity. It is a metabolite that reflects the status of fatty acid oxidation and amino acid metabolism.
|
| ln Vivo |
In vivo, butyrylcarnitine is a naturally occurring metabolite in human plasma. Its levels change in response to metabolic conditions such as heart failure. It serves as a biomarker for the diagnosis and prognosis of heart failure. It is indicative of anomalous lipid and energy metabolism.
|
| Enzyme Assay |
In vitro assays for butyrylcarnitine typically involve the analysis of biological samples (e.g., plasma, serum) by liquid chromatography-tandem mass spectrometry (LC-MS/MS) or other analytical techniques. The compound is used as a reference standard for identification and quantification. Calibration curves are prepared using known concentrations of the compound.
|
| Cell Assay |
Cell-based assays for butyrylcarnitine are not typically performed as it is an endogenous metabolite rather than a drug. However, metabolomics studies may involve culturing cells and measuring butyrylcarnitine levels in the culture medium or cell lysates to assess metabolic flux. Fatty acid oxidation and amino acid metabolism pathways may be evaluated.
|
| Animal Protocol |
In vivo animal experiments for butyrylcarnitine typically involve measuring its levels in plasma or tissues of animal models of metabolic disease (e.g., heart failure, diabetes). Samples are analyzed by LC-MS/MS. The compound is used as a biomarker to monitor disease progression or treatment response. It is not administered as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Butyrylcarnitine (molecular weight 231.29, formula C11H21NO4) is an endogenous metabolite. It is present in human plasma at detectable levels. It is generated during fatty acid and amino acid metabolism. It is excreted in urine. Its levels reflect metabolic status.
|
| Toxicity/Toxicokinetics |
Butyrylcarnitine is an endogenous metabolite and is not associated with significant toxicity. It is a normal constituent of human plasma. No toxicological concerns are associated with this compound as a biomarker. It is for research use only as a reference standard.
|
| References | |
| Additional Infomation |
o-Butyryl-L-carnitine is the optically active form of o-butyrylcarnitine, possessing an L-configuration. It is a metabolite. It is an o-butyrylcarnitine, a saturated fatty acyl-L-carnitine, and a short-chain fatty acyl-L-carnitine.
Butyrylcarnitine (CAS#: 25576-40-3) is a short-chain acylcarnitine and endogenous metabolite. It is a biomarker for heart failure diagnosis and prognosis. It is indicative of lipid and energy metabolism anomalies. Molecular weight: 231.29, formula: C11H21NO4. |
| Molecular Formula |
C11H21NO4
|
|---|---|
| Molecular Weight |
231.28874
|
| Exact Mass |
231.147
|
| CAS # |
25576-40-3
|
| PubChem CID |
213144
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
16
|
| Complexity |
239
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C
|
| InChi Key |
QWYFHHGCZUCMBN-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C11H21NO4/c1-5-6-11(15)16-9(7-10(13)14)8-12(2,3)4/h9H,5-8H2,1-4H3/t9-/m1/s1
|
| Chemical Name |
(3R)-3-butanoyloxy-4-(trimethylazaniumyl)butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~432.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (432.36 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3236 mL | 21.6179 mL | 43.2358 mL | |
| 5 mM | 0.8647 mL | 4.3236 mL | 8.6472 mL | |
| 10 mM | 0.4324 mL | 2.1618 mL | 4.3236 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
